Key Messages To Comprehend: 2023 Focused Update of the 2021 European Society of Cardiology Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
| dc.contributor.author | Akyıldız, Zehra İlke | |
| dc.contributor.author | Baysan, O. | |
| dc.date.accessioned | 2023-12-26T07:28:48Z | |
| dc.date.available | 2023-12-26T07:28:48Z | |
| dc.date.issued | 2023 | |
| dc.description.abstract | [No abstract available] | en_US |
| dc.identifier.doi | 10.24969/hvt.2023.443 | |
| dc.identifier.issn | 1694-7886 | |
| dc.identifier.issn | 1694-7894 | |
| dc.identifier.scopus | 2-s2.0-85179782826 | |
| dc.identifier.uri | https://doi.org/10.24969/hvt.2023.443 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14365/5017 | |
| dc.language.iso | en | en_US |
| dc.publisher | Bishkek: Center for Scientific Research and Development of Education | en_US |
| dc.relation.ispartof | Heart, Vessels and Transplantation | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.subject | acetazolamide | en_US |
| dc.subject | amino terminal pro brain natriuretic peptide | en_US |
| dc.subject | angiotensin receptor antagonist | en_US |
| dc.subject | beta adrenergic receptor blocking agent | en_US |
| dc.subject | canagliflozin | en_US |
| dc.subject | dapagliflozin | en_US |
| dc.subject | dipeptidyl carboxypeptidase inhibitor | en_US |
| dc.subject | diuretic agent | en_US |
| dc.subject | empagliflozin | en_US |
| dc.subject | finerenone | en_US |
| dc.subject | furosemide | en_US |
| dc.subject | hydrochlorothiazide | en_US |
| dc.subject | insulin | en_US |
| dc.subject | iron | en_US |
| dc.subject | iron isomaltose | en_US |
| dc.subject | loop diuretic agent | en_US |
| dc.subject | mineralocorticoid antagonist | en_US |
| dc.subject | sodium glucose cotransporter 2 inhibitor | en_US |
| dc.subject | sotagliflozin | en_US |
| dc.subject | torasemide | en_US |
| dc.subject | acute heart failure | en_US |
| dc.subject | add on therapy | en_US |
| dc.subject | adverse outcome | en_US |
| dc.subject | blood pressure | en_US |
| dc.subject | cardiologist | en_US |
| dc.subject | cardiology | en_US |
| dc.subject | cardiovascular mortality | en_US |
| dc.subject | cardiovascular risk | en_US |
| dc.subject | cerebrovascular accident | en_US |
| dc.subject | chronic disease | en_US |
| dc.subject | chronic kidney failure | en_US |
| dc.subject | comorbidity | en_US |
| dc.subject | coronavirus disease 2019 | en_US |
| dc.subject | death | en_US |
| dc.subject | diabetes mellitus | en_US |
| dc.subject | diabetic ketoacidosis | en_US |
| dc.subject | diabetic nephropathy | en_US |
| dc.subject | disease course | en_US |
| dc.subject | drug efficacy | en_US |
| dc.subject | drug safety | en_US |
| dc.subject | drug tolerability | en_US |
| dc.subject | Editorial | en_US |
| dc.subject | estimated glomerular filtration rate | en_US |
| dc.subject | European | en_US |
| dc.subject | evaluation study | en_US |
| dc.subject | evidence based practice | en_US |
| dc.subject | follow up | en_US |
| dc.subject | health care access | en_US |
| dc.subject | heart failure | en_US |
| dc.subject | heart failure with preserved ejection fraction | en_US |
| dc.subject | heart failure with reduced ejection fraction | en_US |
| dc.subject | heart infarction | en_US |
| dc.subject | heart left ventricle ejection fraction | en_US |
| dc.subject | heart muscle revascularization | en_US |
| dc.subject | hemodialysis | en_US |
| dc.subject | hemodialysis patient | en_US |
| dc.subject | hospital patient | en_US |
| dc.subject | hospitalization | en_US |
| dc.subject | human | en_US |
| dc.subject | iron deficiency | en_US |
| dc.subject | iron therapy | en_US |
| dc.subject | medical society | en_US |
| dc.subject | meta analysis (topic) | en_US |
| dc.subject | morbidity | en_US |
| dc.subject | non insulin dependent diabetes mellitus | en_US |
| dc.subject | outcomes research | en_US |
| dc.subject | practice guideline | en_US |
| dc.subject | prognosis | en_US |
| dc.subject | randomized controlled trial (topic) | en_US |
| dc.subject | risk reduction | en_US |
| dc.subject | sensitivity analysis | en_US |
| dc.subject | treatment outcome | en_US |
| dc.subject | tricuspid valve repair | en_US |
| dc.title | Key Messages To Comprehend: 2023 Focused Update of the 2021 European Society of Cardiology Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure | en_US |
| dc.type | Editorial | en_US |
| dspace.entity.type | Publication | |
| gdc.author.institutional | … | |
| gdc.author.scopusid | 25951323500 | |
| gdc.author.scopusid | 10243313600 | |
| gdc.bip.impulseclass | C5 | |
| gdc.bip.influenceclass | C5 | |
| gdc.bip.popularityclass | C5 | |
| gdc.coar.access | metadata only access | |
| gdc.coar.type | text::journal::editorial | |
| gdc.collaboration.industrial | false | |
| gdc.description.department | İEÜ, Tıp Fakültesi | en_US |
| gdc.description.departmenttemp | Akyildiz, Z.I., Izmir University of Economics, Faculty of Medicine, İzmir, Turkey; Baysan, O., Guven Hospital, Ankara, Turkey | en_US |
| gdc.description.issue | 4 | en_US |
| gdc.description.publicationcategory | Diğer | en_US |
| gdc.description.scopusquality | Q4 | |
| gdc.description.volume | 7 | en_US |
| gdc.description.wosquality | N/A | |
| gdc.identifier.openalex | W4391898146 | |
| gdc.index.type | Scopus | |
| gdc.oaire.accesstype | GOLD | |
| gdc.oaire.diamondjournal | false | |
| gdc.oaire.impulse | 0.0 | |
| gdc.oaire.influence | 2.4895952E-9 | |
| gdc.oaire.isgreen | false | |
| gdc.oaire.keywords | treatment | |
| gdc.oaire.keywords | sodium–glucose co-transporter 2 inhibitors | |
| gdc.oaire.keywords | RC666-701 | |
| gdc.oaire.keywords | 1 | |
| gdc.oaire.keywords | heart failure | |
| gdc.oaire.keywords | Diseases of the circulatory (Cardiovascular) system | |
| gdc.oaire.keywords | guidelines | |
| gdc.oaire.keywords | comorbidities | |
| gdc.oaire.keywords | angiotesin receptor and neprilysin inhibitor | |
| gdc.oaire.keywords | continuous medical education | |
| gdc.oaire.popularity | 2.0536601E-9 | |
| gdc.oaire.publicfunded | false | |
| gdc.openalex.fwci | 0.0 | |
| gdc.openalex.normalizedpercentile | 0.4 | |
| gdc.opencitations.count | 0 | |
| gdc.plumx.mendeley | 10 | |
| gdc.plumx.scopuscites | 0 | |
| gdc.scopus.citedcount | 0 | |
| gdc.virtual.author | Akyıldız, Zehra İlke | |
| relation.isAuthorOfPublication | cf0bff90-dc95-43a1-ba1e-3d2b49f7218c | |
| relation.isAuthorOfPublication.latestForDiscovery | cf0bff90-dc95-43a1-ba1e-3d2b49f7218c | |
| relation.isOrgUnitOfPublication | fbc53f3e-d1d3-4168-afd8-e42cd20bddd9 | |
| relation.isOrgUnitOfPublication | e9e77e3e-bc94-40a7-9b24-b807b2cd0319 | |
| relation.isOrgUnitOfPublication.latestForDiscovery | fbc53f3e-d1d3-4168-afd8-e42cd20bddd9 |
Files
Original bundle
1 - 1 of 1